Reaction

Abdominal Adhesions reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,132 reports · 49 co-occurring drugs

As of the last recalculation, Abdominal Adhesions appears in 3,132 FAERS reports alongside 49 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB (PRR 19.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Adalimumab	1,280	19.6	19.7
Cholestyramine	26	14.4	14.4
Azathioprine	151	11.9	11.9
Diphenoxylate Hydrochloride And Atropine Sulfate	24	11.7	11.7
Vedolizumab	145	11.7	11.7
Octreotide Acetate	50	11.0	11.0
Teduglutide	22	10.9	10.9
Hyoscyamine Sulfate	15	10.9	10.9
Mercaptopurine	24	9.3	9.3
Mesalamine	69	8.3	8.3
Dicyclomine Hydrochloride	17	8.0	8.0
Rizatriptan Benzoate	12	7.9	7.9
Loperamide Hydrochloride And Dimethicone	35	7.3	7.3
Meperidine Hydrochloride	10	7.2	7.2
Lubiprostone	10	7.0	7.1
Promethazine Hydrochloride	18	6.5	6.5
Iron	62	6.3	6.3
Sucralfate Oral	12	5.6	5.6
Sucralfate Oral Suspension	12	5.6	5.6
Sucralfate	20	5.6	5.6
Salmeterol Xinafoate	7	5.4	5.4
Loperamide Hydrochloride	36	5.4	5.4
Pancrelipase	30	5.2	5.2
Infliximab-Dyyb	21	4.8	4.8
Budesonide	41	4.7	4.7
Niraparib	14	4.2	4.2
Loratadine And Pseudoephedrine Sulfate	5	4.2	4.2
Infliximab	133	4.2	4.2
Risankizumab-Rzaa	47	3.9	3.9
Rifaximin	11	3.5	3.5
Multivitamin	26	3.5	3.5
Fondaparinux Sodium	4	3.3	3.3
Copper	21	3.3	3.3
Amphetamine	4	3.2	3.2
Fesoterodine Fumarate	5	3.1	3.1
Drospirenone And Ethinyl Estradiol	20	3.0	3.0
Panitumumab	7	3.0	3.0
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	13	2.8	2.8
Umeclidinium Bromide And Vilanterol Trifenatate	7	2.8	2.8
Bevacizumab	51	2.8	2.8
Interferon Beta-1A	72	2.5	2.5
Levonorgestrel	74	2.5	2.5
Certolizumab Pegol	40	2.3	2.3
Leuprolide Acetate	26	2.2	2.2
Palivizumab	5	2.2	2.2
Cortisone Acetate	3	1.6	1.6
Elexacaftor, Tezacaftor, And Ivacaftor	3	1.6	1.6
Olaparib	5	1.6	1.6
Lifitegrast	3	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.